Acuitybio Overview

  • Founded
  • 2008
  • Status
  • Private
  • Employees
  • 4
  • Latest Deal Type
  • Angel
  • Latest Deal Amount
  • $175K
Latest Deal Amount
  • Investors
  • 3

Acuitybio General Information


Developer of bio-compatible and biodegradable drug-eluting surgical products intended to commercialize novel polymer drug delivery technologies. The company's products are implemented with safety and efficacy in preclinical models, long-term targeted delivery of therapeutic levels of paclitaxel to areas at highest risk for harboring residual cancer cells and can be applied to additional indications besides lung cancer, enabling surgeons to administer during initial tumor removal surgery and prevent recurrence.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Primary Industry
Other Industries
Drug Discovery
Surgical Devices
Primary Office
  • 321 Walnut Street
  • Suite 300
  • Newton, MA 02460
  • United States
+1 (617) 000-0000

Acuitybio Timeline

Financing RoundCaptured Employee CountEstimated Employee Growth
Want detailed data on 2M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Acuitybio Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
6. Angel (individual) 10-Feb-2020 $175K 00.000 Completed Pre-Clinical Trials
5. Angel (individual) 13-Nov-2017 00.000 00.000 000.00 Completed Generating Revenue
4. Grant Completed Generating Revenue
3. Grant 01-Jul-2013 00000 Completed Generating Revenue
2. Grant 16-Sep-2011 $1.4M Completed Generating Revenue
1. Grant 01-Jan-2008 Completed Startup
To view Acuitybio’s complete valuation and funding history, request access »

Acuitybio Cap Table

Stock # of Shares
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series A 0,000,000 00.000000 00.00 00.00 00 00.00 00.00
To view Acuitybio’s complete cap table history, request access »

Acuitybio Executive Team (6)

Name Title Board Seat Contact Info
John Schwartz Ph.D Co-Founder, Board Member, Chairman & Chief Executive Officer
Karen English Chief Financial Officer & Board Member
Oded Biran CBO
Mark Grinstaff Ph.D Co-Founder & Board Member
You’re viewing 4 of 6 executive team members. Get the full list »

Acuitybio Board Members (7)

Name Representing Role Since
Eyal Ron Ph.D Self Board Member & Advisor 000 0000
John Schwartz Ph.D Acuitybio Co-Founder, Board Member, Chairman & Chief Executive Officer 000 0000
Karen English Acuitybio Chief Financial Officer & Board Member 000 0000
Mark Grinstaff Ph.D Self Co-Founder & Board Member 000 0000
Peter Lui Acuitybio Board Member 000 0000
You’re viewing 5 of 7 board members. Get the full list »

Acuitybio Signals

Growth Rate

0.80% Weekly
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers


Similarweb Unique Visitors


Majestic Referring Domains


PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Acuitybio Investors (3)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
U.S. Department of Health and Human Services Government 000 0000 000000 0
National Cancer Institute Government 000 0000 000000 0
Internal Revenue Service Government 000 0000 000000 0
To view Acuitybio’s complete investors history, request access »